Metropolis Healthcare Limited (BOM:542650)
India · Delayed Price · Currency is INR | Market Cap | 115.47B +2.5% |
| Revenue (ttm) | 17.10B +21.8% |
| Net Income | 2.02B +32.6% |
| EPS | 10.10 +37.1% |
| Shares Out | n/a |
| PE Ratio | 57.27 |
| Forward PE | 42.30 |
| Dividend | 2.00 (0.36%) |
| Ex-Dividend Date | May 19, 2026 |
| Volume | 6,262 |
| Open | 546.90 |
| Previous Close | 540.65 |
| Day's Range | 538.55 - 560.80 |
| 52-Week Range | 413.00 - 608.95 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 655.53 (+17.76%) |
| Earnings Date | Aug 4, 2026 |
About Metropolis Healthcare
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India and internationally. The company offers routine and specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; clinical trial research, hospital lab management, and home collection services; radiology services, including X-ray, sonography and ECG; and next-generation sequencing services. It also provides diagnosti... [Read more]
Financial Performance
In fiscal year 2026, Metropolis Healthcare's revenue was 16.46 billion, an increase of 23.64% compared to the previous year's 13.31 billion. Earnings were 1.90 billion, an increase of 31.08%.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for 542650 stock is "Buy." The 12-month stock price target is ₹655.53, which is an increase of 17.76% from the latest price.
News
Metropolis Healthcare Transcript: Q1 26/27
Q1 FY 2027 delivered 17% revenue growth and 27% EBITDA growth, driven by strong patient volumes, network expansion, and specialty diagnostics. Margin expansion and integration of acquisitions, especially Core Diagnostics, contributed to improved profitability. Guidance for FY 2027 remains at 14%-16% revenue growth and 27%-28% EBITDA margin.
Metropolis Healthcare Quarterly report: Q1 2027
Metropolis Healthcare has published its Q1 2027 quarterly earnings report on August 4, 2026.
Metropolis Healthcare Slides: Q1 2027
Metropolis Healthcare has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 4, 2026.
Earnings To Watch: Metropolis Healthcare Ltd (BOM:542650) Q1 2027 -- GF Value Sees 16% Upside
Earnings To Watch: Metropolis Healthcare Ltd (BOM:542650) Q1 2027 -- GF Value Sees 16% Upside
Metropolis Healthcare concall update: Management targets 13-15% growth in FY27 despite Q4 miss
Metropolis Healthcare shares traded higher on Thursday after the company’s management maintained a bullish growth outlook for FY27 despite a Q4 miss, with investors taking note of strong year-on-year ...
Metropolis Healthcare Transcript: Q4 25/26
FY 2026 saw 23.6% group revenue growth and margin expansion, driven by Specialty and TruHealth segments, digital channels, and successful integration of acquisitions. Guidance targets 14%-15% CAGR and 27%-28% EBITDA margin over three years, with continued network and digital expansion.
Metropolis Healthcare Quarterly report: Q4 2026
Metropolis Healthcare has published its Q4 2026 quarterly earnings report on May 13, 2026.
Metropolis Healthcare Slides: Q4 2026
Metropolis Healthcare has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 13, 2026.
Metropolis Healthcare Annual report: Q4 2026
Metropolis Healthcare has published its Q4 2026 annual report on May 13, 2026.
Metropolis Healthcare Transcript: Q3 25/26
Q3 saw 26% group revenue growth and 29% organic EBITDA growth year-on-year, with strong performance across B2C and B2B segments and expanding margins. Strategic focus on genomics, digital, and network expansion continues, while a 3:1 bonus share issue was announced.
Metropolis Healthcare Quarterly report: Q3 2026
Metropolis Healthcare has published its Q3 2026 quarterly earnings report on February 4, 2026.
Metropolis Healthcare Slides: Q3 2026
Metropolis Healthcare has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 4, 2026.
Metropolis Healthcare Ltd (BOM:542650) Q3 2026: Everything You Need To Know Ahead Of Earnings
Metropolis Healthcare Ltd (BOM:542650) Q3 2026: Everything You Need To Know Ahead Of Earnings
Metropolis Healthcare launches Centre of Genomics to scale precision diagnostics in India
Metropolis Healthcare Limited on Tuesday announced the launch of its Centre of Genomics, marking a strategic expansion of its advanced...
Metropolis Healthcare shares rise over 3% after strong Q3 FY26 business update
Shares of Metropolis Healthcare traded higher in Monday’s session after the diagnostics company reported a strong business performance for the...
Metropolis Healthcare reports 26% revenue growth in Q3 FY26; wellness and specialty segments drive demand
Metropolis Healthcare Limited has reported a strong operating performance in the December quarter of FY26, with consolidated revenue rising around...
Metropolis Healthcare Transcript: Q2 25/26
Group revenue grew 23% year-over-year with strong organic margin expansion and double-digit volume growth. Integration of recent acquisitions is progressing, and guidance for margin and top-line growth is maintained for FY2026.
Metropolis Healthcare Quarterly report: Q2 2026
Metropolis Healthcare has published its Q2 2026 quarterly earnings report on November 6, 2025.
Metropolis Healthcare Slides: Q2 2026
Metropolis Healthcare has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 6, 2025.
Metropolis Healthcare shares jump over 3% as Q2 revenue rises 22.7% YoY to Rs 429 crore, net profit up 13.2%
Metropolis Healthcare shares jumped more than 3% in early trade after the diagnostics company reported a strong set of earnings...
What To Expect From Metropolis Healthcare Ltd (BOM:542650) Q2 2026 Earnings
What To Expect From Metropolis Healthcare Ltd (BOM:542650) Q2 2026 Earnings
Metropolis Healthcare incorporates new subsidiary Metropolis Quality Solutions
Metropolis Healthcare Limited on Tuesday announced the incorporation of a new wholly owned subsidiary, Metropolis Quality Solutions Private Limited, effective September 15, 2025. The newly incorporate...
Metropolis Healthcare shares jump nearly 3% following Q1 results; Company projects over 12% revenue growth in FY26
Shares of Metropolis Healthcare Ltd surged 2.86% to ₹2,065.90 on Monday, adding ₹57.50 in early trade. The stock, listed on NSE, has a market capitalisation of ₹10,513.48 crore and has traded between ...
Metropolis Healthcare Transcript: Q1 25/26
Q1 FY2026 saw 23% group revenue growth and 13.2% organic growth, with margin expansion and strong performance in specialty and preventive diagnostics. Integration of recent acquisitions is on track, and further growth is expected in Tier 2/3 markets and B2C share.
Metropolis Healthcare Quarterly report: Q1 2026
Metropolis Healthcare has published its Q1 2026 quarterly earnings report on August 8, 2025.